N-heterocyclic five-membered ring-containing capsid protein assembly inhibitor, pharmaceutical composition thereof, and use thereof

1. A compound of Formula I, a stereoisomer, a tautomer, a geometric isomer, a solvate, a hydrate, or a pharmaceutically acceptable salt thereof,

wherein,

X and Y each independently represent CR 7 , and said R 7 is independently selected from the group consisting of hydrogen, C 3-4 cycloalkyl, —CN, fluoro, chloro, bromo and C 1-3 alkyl, wherein said C 1-3 alkyl is optionally substituted with one or more fluoro;

ring A is selected from the group consisting of phenyl and 5- to 10-membered heteroaryl;

R 1 , R 2 and R 3 are each independently selected from the group consisting of hydrogen, fluoro, chloro, bromo, —CHF 2 , —CH 2 F, —CF 3 , —CN, C 1-3 alkyl, and C 3-4 cycloalkyl;

R 4 is selected from the group consisting of hydrogen, C 1-3 alkyl and C 3-4 cycloalkyl;

R 5 is selected from the group consisting of C 1-6 alkyl, C 2-6 alkenyl, C 2-6 alkynyl, 3- to 7-membered cycloalkyl and 3- to 7-membered heterocycloalkyl, wherein said C 1-6 alkyl, C 2-6 alkenyl, C 2-6 alkynyl, 3- to 7-membered cycloalkyl and 3- to 7-membered heterocycloalkyl are optionally substituted with the group(s) selected from the group consisting of halo, 3- to 4-membered cycloalkyl, 3- to 4-membered heterocycloalkyl, —OR 8 , oxo, —CN, —C(O)OR 8 , —SO 2 R 8 , —C(O)N(R 8 ) 2 , and C 1-3 alkyl, wherein C 1-3 alkyl is optionally substituted with one or more groups selected from the group consisting of fluoro, —CN and —OH; and

each R 8 is independently selected from the group consisting of hydrogen and C 1-3 alkyl.

2. The compound of Formula I, a stereoisomer, a tautomer, a geometric isomer, a solvate, a hydrate, or a pharmaceutically acceptable salt thereof according to claim 1 , wherein:

X and Y each independently represent CR 7 , and said R 7 is independently selected from the group consisting of hydrogen, fluoro, chloro, bromo and C 1-3 alkyl, wherein the C 1-3 alkyl is optionally substituted with one or more fluoro;

alternatively, R 7 is independently selected from the group consisting of hydrogen, fluoro, chloro, bromo, and C 1-3 alkyl;

alternatively, R 7 is independently selected from the group consisting of hydrogen, fluoro, chloro, bromo, and methyl; and

alternatively, R 7 is independently selected from the group consisting of hydrogen, chloro, bromo, and methyl.

3. The compound of Formula I, a stereoisomer, a tautomer, a geometric isomer, a solvate, a hydrate, or a pharmaceutically acceptable salt thereof according to claim 1 , wherein:

ring A is selected from the group consisting of phenyl, 5-membered heteroaryl, 6-membered heteroaryl, 7-membered heteroaryl, 8-membered heteroaryl, 9-membered heteroaryl and 10-membered heteroaryl;

alternatively, ring A is selected from the group consisting of phenyl and 6-membered heteroaryl;

alternatively, ring A is selected from phenyl; and

alternatively, the “heteroaryl” in the above definitions of ring A contains 1 or 2 N atoms.

4. The compound of Formula I, a stereoisomer, a tautomer, a geometric isomer, a solvate, a hydrate, or a pharmaceutically acceptable salt thereof according to claim 1 , wherein:

R 1 is selected from the group consisting of hydrogen, fluoro, chloro, —CHF 2 , —CN, —CF 3 and methyl; and

alternatively, R 1 is selected from the group consisting of hydrogen and fluoro.

5. The compound of Formula I, a stereoisomer, a tautomer, a geometric isomer, a solvate, a hydrate, or a pharmaceutically acceptable salt thereof according to claim 1 , wherein:

R 2 is selected from the group consisting of hydrogen, fluoro, chloro, and bromo; and

alternatively, R 2 is selected from the group consisting of hydrogen and fluoro.

6. The compound of Formula I, a stereoisomer, a tautomer, a geometric isomer, a solvate, a hydrate, or a pharmaceutically acceptable salt thereof according to claim 1 , wherein:

R 3 is selected from the group consisting of hydrogen, fluoro, chloro, —CHF 2 , —CN, —CF 3 , and methyl;

alternatively, R 3 is selected from the group consisting of hydrogen, fluoro, chloro, —CN, and methyl.

7. The compound of Formula I, a stereoisomer, a tautomer, a geometric isomer, a solvate, a hydrate, or a pharmaceutically acceptable salt thereof according to claim 1 , wherein:

R 1 is selected from the group consisting of hydrogen, fluoro, chloro, —CHF 2 , —CN, —CF 3 and methyl, and at least one of R 1 and R 3 is fluoro or hydrogen.

8. The compound of Formula I, a stereoisomer, a tautomer, a geometric isomer, a solvate, a hydrate, or a pharmaceutically acceptable salt thereof according to claim 1 , wherein:

one of R 1 and R 3 is selected from the group consisting of hydrogen and fluoro, and the other is selected from the group consisting of hydrogen, fluoro, chloro, —CHF 2 , —CN, —CF 3 , and methyl;

alternatively, one of R 1 and R 3 is hydrogen, and the other is selected from the group consisting of fluoro, chloro, —CHF 2 , —CN, —CF 3 and methyl;

alternatively, R 2 is selected from the group consisting of fluoro, chloro, and bromo, and one of R 1 and R 3 is hydrogen, and the other is selected from the group consisting of hydrogen, fluoro, chloro, —CHF 2 , —CN, —CF 3 and methyl;

alternatively, R 2 is fluoro, and one of R 1 and R 3 is hydrogen, and the other is selected from the group consisting of fluoro, chloro and —CN;

alternatively, R 2 is fluoro, R 1 is hydrogen, and R 3 is —CN or chloro; and

alternatively, R 2 is fluoro, R 1 is hydrogen, and R 3 is —CN.

9. The compound of Formula I, a stereoisomer, a tautomer, a geometric isomer, a solvate, a hydrate, or a pharmaceutically acceptable salt thereof according to claim 1 , wherein:

R 4 is selected from the group consisting of hydrogen and C 1-3 alkyl; and/or R 8 is selected from the group consisting of hydrogen and methyl;

alternatively, R 4 is methyl or hydrogen; and

alternatively, R 4 is methyl.

10. The compound of Formula I, a stereoisomer, a tautomer, a geometric isomer, a solvate, a hydrate, or a pharmaceutically acceptable salt thereof according to claim 1 , wherein:

R 5 is selected from the group consisting of C 1-4 alkyl, C 2-4 alkenyl, C 2-4 alkynyl, 3- to 6-membered cycloalkyl and 4- to 6-membered heterocycloalkyl, wherein said C 1-4 alkyl, C 2-4 alkenyl, C 2-4 alkynyl, 3- to 6-membered cycloalkyl or 4- to 6-membered heterocycloalkyl is optionally substituted with the group(s) selected from the group consisting of halo, 3- to 4-membered cycloalkyl, 3- to 4-membered heterocycloalkyl, —OR 8 , oxo, —CN, —C(O)OR 8 , —SO 2R 8 , —C(O)N(R 8 ) 2 , and C 1-3 alkyl, wherein C 1-3 alkyl is optionally substituted with one or more groups selected from the group consisting of fluoro, —CN and —OH;

alternatively, R 5 is selected from the group consisting of C 1-4 alkyl, C 2-4 alkenyl, C 2-4 alkynyl, 4-to 6-membered cycloalkyl and 4- to 6-membered heterocycloalkyl, wherein said C 1-4 alkyl, C 2-4 alkenyl, C 2-4 alkynyl, 4- to 6-membered cycloalkyl or 4- to 6-membered heterocycloalkyl is optionally substituted with the group(s) selected from the group consisting of halo, 3- to 4-membered cycloalkyl, 3- to 4-membered heterocycloalkyl, —OR 8 , oxo, —CN, —C(O)OR 8 , —SO 2 R 8 , —C(O)N(R 8 ) 2 , and C 1-3 alkyl, wherein C 1-3 alkyl is optionally substituted with one or more groups selected from the group consisting of fluoro, —CN and —OH;

alternatively, R 5 is selected from the group consisting of C 1-4 alkyl, C 2-4 alkenyl, C 2-4 alkynyl, 3-to 6-membered cycloalkyl and 4- to 6-membered heterocycloalkyl, wherein said C 1-4 alkyl, C 2-4 alkenyl, C 2-4 alkynyl, 3- to 6-membered cycloalkyl or 4- to 6-membered heterocycloalkyl is optionally substituted with the group(s) selected from the group consisting of halo, oxo, —OH, —CN, —C(O)OR 8 , —C(O)N(R 8 ) 2 , and C 1-3 alkyl, wherein C 1-3 alkyl is optionally substituted with one or more groups selected from the group consisting of fluoro and OH;

alternatively, R 5 is selected from the group consisting of C 1-4 alkyl, C 2-4 alkenyl, C 2-4 alkynyl, 3-to 6-membered cycloalkyl and 4- to 6-membered heterocycloalkyl, wherein said C 1-4 alkyl, C 2-4 alkenyl, C 2-4 alkynyl, 3- to 6-membered cycloalkyl or 4- to 6-membered heterocycloalkyl is optionally substituted with the group(s) selected from the group consisting of halo, —OH, —CN, —C(O)OR 8 , —C(O)N(R 8 ) 2 , and C 1-3 alkyl, wherein C 1-3 alkyl is optionally substituted with one or more groups selected from the group consisting of fluoro and OH;

alternatively, R 5 is selected from the group consisting of C 1-4 alkyl, C 2-4 alkenyl, C 2-4 alkynyl, 4-to 6-membered cycloalkyl and 4- to 6-membered heterocycloalkyl, wherein said C 1-4 alkyl, C 2-4 alkenyl, C 2-4 alkynyl, 4- to 6-membered cycloalkyl or 4- to 6-membered heterocycloalkyl is optionally substituted with the group(s) selected from the group consisting of halo, —OH, —CN, —C(O)OR 8 , —C(O)N(R 8 ) 2 , and C 1-3 alkyl, wherein C 1-3 alkyl is optionally substituted with one or more groups selected from the group consisting of fluoro and OH;

alternatively, R 5 is selected from the group consisting of C 1-4 alkyl, C 2-4 alkynyl, 3- to 6-membered cycloalkyl and 4- to 6-membered heterocycloalkyl, wherein said C 1-4 alkyl, C 2-4 alkynyl, 3- to 6-membered cycloalkyl or 4- to 6-membered heterocycloalkyl is optionally substituted with the group(s) selected from the group consisting of halo, oxo, —OH, —C(O)N(R 8 ) 2 , —C(O)OR 8 , and C 1-3 alkyl, wherein C 1-3 alkyl is optionally substituted with one or more groups selected from the group consisting of OH and fluoro;

alternatively, R 5 is selected from the group consisting of C 1-4 alkyl, C 2-4 alkynyl, 3- to 6-membered cycloalkyl and 4- to 6-membered heterocycloalkyl, wherein said C 1-4 alkyl, C 2-4 alkynyl, 3- to 6-membered cycloalkyl or 4- to 6-membered heterocycloalkyl is optionally substituted with the group(s) selected from the group consisting of halo, —OH, —C(O)N(R 8 ) 2 , —C(O)OR 8 , and C 1-3 alkyl, wherein C 1-3 alkyl is optionally substituted with the group(s) selected from the group consisting of OH and fluoro;

alternatively, R 5 is selected from the group consisting of C 1-4 alkyl, C 2-4 alkynyl, 4- to 6-membered cycloalkyl and 4- to 6-membered heterocycloalkyl, wherein said C 1-4 alkyl, C 2-4 alkynyl, 4- to 6-membered cycloalkyl or 4- to 6-membered heterocycloalkyl is optionally substituted with the group(s) selected from the group consisting of halo, —OH, —C(O)OR 8 , and C 1-3 alkyl, wherein C 1-3 alkyl is optionally substituted with OH;

alternatively, R 5 is selected from the group consisting of C 1-4 alkyl, C 2-4 alkynyl, 3- to 6-membered cycloalkyl and 4- to 6-membered heterocycloalkyl, wherein said C 1-4 alkyl is optionally substituted with the group(s) selected from the group consisting of halo, —OH and —C(O)OR 8 , wherein the 3-to 6-membered cycloalkyl or 4- to 6-membered heterocycloalkyl is optionally substituted with the group(s) selected from the group consisting of: oxo, —OH, fluoro, —C(O)N(R 8 ) 2 , and C 1-3 alkyl, wherein C 1-3 alkyl is optionally substituted with one or more groups selected from the group consisting of OH and fluoro;

alternatively, R 5 is selected from the group consisting of C 1-4 alkyl, C 2-4 alkynyl, 3- to 6-membered cycloalkyl and 4- to 6-membered heterocycloalkyl, wherein said C 1-4 alkyl is optionally substituted with the group(s) selected from the group consisting of halo, —OH and —C(O)OR 8 , wherein the 3-to 6-membered cycloalkyl or 4- to 6-membered heterocycloalkyl is optionally substituted with the group(s) selected from the group consisting of —OH, fluoro, —C(O)N(R 8 ) 2 , and C 1-3 alkyl, wherein C 1-3 alkyl is optionally substituted with the group(s) selected from the group consisting of OH and fluoro;

alternatively, R 5 is selected from the group consisting of C 1-4 alkyl, C 3 alkynyl, 3- to 6-membered cycloalkyl and 4- to 6-membered heterocycloalkyl, wherein said C 1-4 alkyl group is optionally substituted with the group(s) selected from the group consisting of fluoro, —OH and —C(O)OCH 3 , wherein said 3- to 6-membered cycloalkyl or 4- to 6-membered heterocycloalkyl is optionally substituted with the group(s) selected from the group consisting of oxo, —OH, fluoro, —C(O)NHCH 3 , and methyl, wherein methyl is optionally substituted with one or more groups selected from the group consisting of OH and fluoro;

alternatively, R 5 is selected from the group consisting of C 1-4 alkyl, C 3 alkynyl, 3- to 6-membered cycloalkyl and 4- to 6-membered heterocycloalkyl, wherein said C 1-4 alkyl is optionally substituted with the group(s) selected from the group consisting of fluoro, —OH and —C(O)OCH 3 , wherein said 3- to 6-membered cycloalkyl or 4- to 6-membered heterocycloalkyl is optionally substituted with the group(s) selected from the group consisting of —OH, fluoro, —C(O)NHCH 3 , and methyl, wherein methyl is optionally substituted with the group(s) selected from the group consisting of OH and fluoro; and

alternatively, the “heterocycloalkyl” in the definitions of le contains 1 or 2 heteroatoms selected from the group consisting of N, O and S.

11. The compound of Formula I, a stereoisomer, a tautomer, a geometric isomer, a solvate, a hydrate, or a pharmaceutically acceptable salt thereof according to claim 1 , wherein:

the structural unit

is selected from the group consisting of

alternatively, the structural unit

is selected from

alternatively, the structural unit

is selected from;

alternatively, the structural unit

is selected from

alternatively, the structural unit

is selected from the group consisting of

12. The compound of Formula I, a stereoisomer, a tautomer, a geometric isomer, a solvate, a hydrate, or a pharmaceutically acceptable salt thereof according to claim 1 , wherein:

the structural unit

is selected from

alternatively, the structural unit

is selected from the group consisting of

13. The compound of Formula I, a stereoisomer, a tautomer, a geometric isomer, a solvate, a hydrate, or a pharmaceutically acceptable salt thereof according to claim 1 , wherein:

the structural unit

is selected from the group consisting of

alternatively, the structural unit

is selected from the group consisting of

14. The compound of Formula I, a stereoisomer, a tautomer, a geometric isomer, a solvate, a hydrate, or a pharmaceutically acceptable salt thereof according to claim 1 , wherein, the compound of formula I, a stereoisomer, a tautomer, a geometric isomer, a solvate, a hydrate, or a pharmaceutically acceptable salt thereof is selected from a compound of Formula II, Formula III or Formula IV, a stereoisomer, a tautomer, a geometric isomer, a solvate, a hydrate, or a pharmaceutically acceptable salt thereof,

wherein R 1 , R 2 , R 3 , R 4 , R 5 , X, and Y are as defined in claim 1 .

15. A compound, a stereoisomer, a tautomer, a geometric isomer, a solvate, a hydrate, or a pharmaceutically acceptable salt thereof, selected from the group consisting of:

16. The compound of Formula I, a stereoisomer, a tautomer, a geometric isomer, or a pharmaceutically acceptable salt thereof according to claim 1 , wherein R 8 is selected from the group consisting of hydrogen and methyl.

17. The compound of Formula I, a stereoisomer, a tautomer, a geometric isomer, or a pharmaceutically acceptable salt thereof according to claim 1 , wherein ring A is selected from the group consisting of phenyl and pyridyl.

18. The compound of Formula I, a stereoisomer, a tautomer, a geometric isomer, or a pharmaceutically acceptable salt thereof according to claim 10 , wherein R 5 is selected from the group consisting of C 1-4 alkyl, C 2-4 alkynyl, 4- to 6-membered cycloalkyl and 4- to 6-membered heterocycloalkyl, wherein said C 1-4 alkyl is optionally substituted with the group(s) selected from the group consisting of halo, —OH and —C(O)OR 8 , wherein the 4- to 6-membered cycloalkyl or 4- to 6-membered heterocycloalkyl is optionally substituted with the group(s) selected from the group consisting of —OH, and C 1-3 alkyl, wherein C 1-3 alkyl is optionally substituted with OH.

19. A pharmaceutical composition comprising a compound of Formula I, a stereoisomer, a tautomer, a geometric isomer, a solvate, a hydrate, or a pharmaceutically acceptable salt thereof according to claim 1 ; optionally, the pharmaceutical composition further comprises a pharmaceutically acceptable excipient.

20. A method for treating a disease caused by hepatitis B virus (HBV) infection, comprising administering to a mammal in need of such treatment a therapeutically effective amount of a compound of Formula I, a stereoisomer, a tautomer, a geometric isomer, a solvate, a hydrate, or a pharmaceutically acceptable salt thereof according to claim 1 .